CN104662017A - 酰胺衍生物及其作为卢立康唑药物制剂的稳定性指标的用途 - Google Patents

酰胺衍生物及其作为卢立康唑药物制剂的稳定性指标的用途 Download PDF

Info

Publication number
CN104662017A
CN104662017A CN201380047770.5A CN201380047770A CN104662017A CN 104662017 A CN104662017 A CN 104662017A CN 201380047770 A CN201380047770 A CN 201380047770A CN 104662017 A CN104662017 A CN 104662017A
Authority
CN
China
Prior art keywords
luliconazole
pharmaceutical preparation
composition
amide derivatives
growing amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380047770.5A
Other languages
English (en)
Chinese (zh)
Inventor
增田孝明
山口博志
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pola Pharma Inc
Nihon Nohyaku Co Ltd
Original Assignee
Pola Pharma Inc
Nihon Nohyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pola Pharma Inc, Nihon Nohyaku Co Ltd filed Critical Pola Pharma Inc
Publication of CN104662017A publication Critical patent/CN104662017A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201380047770.5A 2012-09-14 2013-02-19 酰胺衍生物及其作为卢立康唑药物制剂的稳定性指标的用途 Pending CN104662017A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012-202696 2012-09-14
JP2012202696A JP5460797B1 (ja) 2012-09-14 2012-09-14 アミド誘導体及び安定性指標としてのその使用
PCT/JP2013/055025 WO2014041825A1 (en) 2012-09-14 2013-02-19 Amide derivative and use of the same as stability index of a luliconazole pharmaceutical formulation

Publications (1)

Publication Number Publication Date
CN104662017A true CN104662017A (zh) 2015-05-27

Family

ID=47884458

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380047770.5A Pending CN104662017A (zh) 2012-09-14 2013-02-19 酰胺衍生物及其作为卢立康唑药物制剂的稳定性指标的用途

Country Status (7)

Country Link
US (1) US9145401B2 (enExample)
EP (1) EP2895480A1 (enExample)
JP (1) JP5460797B1 (enExample)
CN (1) CN104662017A (enExample)
IN (1) IN2015DN02930A (enExample)
RU (1) RU2612557C2 (enExample)
WO (1) WO2014041825A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5688406B2 (ja) 2009-04-09 2015-03-25 株式会社ポーラファルマ 抗真菌医薬組成物
EP2416757A2 (en) 2009-04-09 2012-02-15 Pola Pharma Inc. Antimycotic pharmaceutical composition
EP2470178B1 (en) 2009-08-25 2018-10-17 Pola Pharma Inc. Antimycotic pharmaceutical composition
US8962669B2 (en) 2010-06-11 2015-02-24 Pola Pharma Inc. Antimycotic pharmaceutical composition
CN104619704B (zh) 2012-09-14 2017-12-05 宝丽制药股份有限公司 表面自由能用于分化评价晶体的用途，基于表面自由能作为指标评价的晶体，以及通过包含所述晶体制备的药物组合物
IN2015DN02376A (enExample) 2012-09-14 2015-09-04 Pola Pharma Inc
JP5589130B1 (ja) 2012-09-14 2014-09-10 株式会社ポーラファルマ 結晶及び該結晶を含有してなる医薬製剤
JP5589110B1 (ja) 2013-03-08 2014-09-10 株式会社ポーラファルマ 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物
JP5680161B1 (ja) 2013-09-06 2015-03-04 株式会社ポーラファルマ 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物
JP5587488B1 (ja) * 2013-12-12 2014-09-10 株式会社ポーラファルマ ルリコナゾールを含有する製剤の評価方法及び指標物質
JP5926756B2 (ja) * 2014-03-26 2016-05-25 株式会社ポーラファルマ ルリコナゾールを含有する製剤の評価方法及び指標物質
JP5623671B1 (ja) * 2014-07-23 2014-11-12 株式会社ポーラファルマ ルリコナゾールを含有する製剤の評価方法及び指標物質
EP3230280A4 (en) * 2014-12-12 2018-05-09 Glenmark Pharmaceuticals Limited Process for preparation of luliconazole
JP7259873B2 (ja) * 2019-02-07 2023-04-18 株式会社島津製作所 分析方法、分析装置およびプログラム

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2005958A1 (en) * 2006-03-08 2008-12-24 Nihon Nohyaku Co., Ltd. External pharmaceutical composition
WO2011155640A1 (en) * 2010-06-11 2011-12-15 Pola Pharma Inc. Antimycotic pharmaceutical composition
CN102395274A (zh) * 2009-02-13 2012-03-28 托派卡医药股份有限公司 抗真菌制剂

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3081766B2 (ja) 1994-05-06 2000-08-28 東興薬品工業株式会社 角質貯留型抗真菌外用組成物
CN1091596C (zh) 1995-07-08 2002-10-02 日本农药株式会社 抗真菌剂及其化合物和它们的制备方法
JP2002114680A (ja) 2000-07-31 2002-04-16 Nippon Nohyaku Co Ltd 抗真菌剤
JP5184341B2 (ja) 2006-03-08 2013-04-17 日本農薬株式会社 外用の医薬組成物
JP5184342B2 (ja) 2006-03-08 2013-04-17 日本農薬株式会社 外用の医薬組成物
HUE030028T2 (en) 2007-09-05 2017-04-28 Pola Pharma Inc Antifungal drug
US20100204293A1 (en) 2007-09-05 2010-08-12 Pola Pharma Inc. Pharmaceutical composition
WO2009031643A1 (ja) * 2007-09-05 2009-03-12 Pola Pharma Inc. 抗真菌組成物
EP2416757A2 (en) 2009-04-09 2012-02-15 Pola Pharma Inc. Antimycotic pharmaceutical composition
JP5688406B2 (ja) 2009-04-09 2015-03-25 株式会社ポーラファルマ 抗真菌医薬組成物
EP2470178B1 (en) 2009-08-25 2018-10-17 Pola Pharma Inc. Antimycotic pharmaceutical composition
RU2621615C2 (ru) 2012-09-14 2017-06-06 Пола Фарма Инк. Фармацевтическая композиция, содержащая луликоназол
CN104619704B (zh) 2012-09-14 2017-12-05 宝丽制药股份有限公司 表面自由能用于分化评价晶体的用途，基于表面自由能作为指标评价的晶体，以及通过包含所述晶体制备的药物组合物
JP5589130B1 (ja) 2012-09-14 2014-09-10 株式会社ポーラファルマ 結晶及び該結晶を含有してなる医薬製剤
IN2015DN02376A (enExample) 2012-09-14 2015-09-04 Pola Pharma Inc
JP5589110B1 (ja) 2013-03-08 2014-09-10 株式会社ポーラファルマ 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物
JP5587488B1 (ja) * 2013-12-12 2014-09-10 株式会社ポーラファルマ ルリコナゾールを含有する製剤の評価方法及び指標物質

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2005958A1 (en) * 2006-03-08 2008-12-24 Nihon Nohyaku Co., Ltd. External pharmaceutical composition
EP2005958A4 (en) * 2006-03-08 2010-09-15 Nihon Nohyaku Co Ltd TOPICAL PHARMACEUTICAL COMPOSITION
CN102395274A (zh) * 2009-02-13 2012-03-28 托派卡医药股份有限公司 抗真菌制剂
WO2011155640A1 (en) * 2010-06-11 2011-12-15 Pola Pharma Inc. Antimycotic pharmaceutical composition

Also Published As

Publication number Publication date
JP2014058449A (ja) 2014-04-03
JP5460797B1 (ja) 2014-04-02
RU2612557C2 (ru) 2017-03-09
RU2015113587A (ru) 2016-11-10
WO2014041825A1 (en) 2014-03-20
IN2015DN02930A (enExample) 2015-09-18
US20150191456A1 (en) 2015-07-09
EP2895480A1 (en) 2015-07-22
US9145401B2 (en) 2015-09-29

Similar Documents

Publication Publication Date Title
CN104662017A (zh) 酰胺衍生物及其作为卢立康唑药物制剂的稳定性指标的用途
JP6215102B2 (ja) 医薬組成物
CA2760084C (en) 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
KR101343291B1 (ko) 외용의 의약 조성물
WO2020028820A1 (en) Topical compositions and methods of preparation and use
RU2768826C2 (ru) Составы на основе ингибиторов pde-4 для местного применения и способы их применения
HUE035882T2 (en) 1,2,4-triazolo [4,3-A] pyridine compounds and their use as positive allosteric modulators of MGLUR2 receptors
JP2008303194A (ja) 香料造粒物
DE60119378T2 (de) Benzofuranderivate und pharmazeutische zusammensetzungen, die diese enthalten
JP5623671B1 (ja) ルリコナゾールを含有する製剤の評価方法及び指標物質
JP5722364B2 (ja) 医薬組成物
JP2009280573A (ja) 内服用体臭抑制剤
WO2025078256A1 (en) Composition
JPWO2017069230A1 (ja) 皮膚用の医薬組成物
WO1996006091A1 (de) Verwendung von substituierten 6-amino-4h-pyranen
JP6067399B2 (ja) 医薬組成物
WO2025240804A1 (en) Novel compositions, devices and methods
JP6077081B2 (ja) 医薬組成物
JP5719985B2 (ja) ジフェニルメチルピペラジン誘導体
KR20180030025A (ko) 질환의 치료를 위한 헤테로아릴 카보나이트릴
CN121013710A (zh) 包括激酶抑制剂的局部医药制品
JP5709499B2 (ja) リボフラビン又はその誘導体の安定化
JP5730340B2 (ja) 貯留型医薬組成物
KR20170137117A (ko) 피부용의 의약 조성물
JPWO2015152168A1 (ja) 軟膏基剤および軟膏

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150527